{
  "model": "gpt-5.2",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 3,
  "result": {
    "text": "- [x] `output/study_overview.json` written\n- [x] `output/quantitative_findings.json` written\n- [x] `output/claim_audit.json` written\n- [x] `output/public_summary.json` written",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f625a13d88193aba18cf17dff78f9\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\".\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":true,\\\"respect_gemini_ignore\\\":true}}\",\n  \"call_id\": \"call_krovVffcabrHwsEFjdY9YCTe\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": ".",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "input/\noutput/\nschemas/\nTASK.md",
            "callId": "call_krovVffcabrHwsEFjdY9YCTe"
          }
        ],
        "usage": {
          "promptTokens": 561,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 34,
          "totalTokens": 639
        },
        "costUsd": 0.00207375
      },
      {
        "step": 2,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f625af9a881938893586f4a165cb1\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"TASK.md\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_vmO3blPm7Q9hdu9LaoPw8BAt\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "call_vmO3blPm7Q9hdu9LaoPw8BAt"
          }
        ],
        "usage": {
          "promptTokens": 658,
          "cachedTokens": 0,
          "responseTokens": 29,
          "thinkingTokens": 0,
          "totalTokens": 687
        },
        "costUsd": 0.0015574999999999999
      },
      {
        "step": 3,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f625e64a8819384da710d5b466b97\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"dir_path\\\":\\\"schemas\\\",\\\"ignore\\\":null,\\\"file_filtering_options\\\":{\\\"respect_git_ignore\\\":true,\\\"respect_gemini_ignore\\\":true}}\",\n  \"call_id\": \"call_G2r1FVU3qjx4WmvRqlAkea0f\",\n  \"name\": \"list_directory\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": {
                "respect_git_ignore": true,
                "respect_gemini_ignore": true
              }
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "call_G2r1FVU3qjx4WmvRqlAkea0f"
          }
        ],
        "usage": {
          "promptTokens": 1109,
          "cachedTokens": 0,
          "responseTokens": 44,
          "thinkingTokens": 25,
          "totalTokens": 1178
        },
        "costUsd": 0.00290675
      },
      {
        "step": 4,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f626104448193a07e00762872f334\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"input/report.md\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_hsErmQpwqizB6EnArXi4uDy1\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f62610454819391975fa8823da5d6\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/study_overview.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_RXuyz4bLRs0ozrrDTXwNiUDP\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f6261045c8193869e239b5043fe84\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/quantitative_findings.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_FJjNGkDoE2iZ2LsYioCCnGNF\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f62610460819381ffe52fd49f2712\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/claim_audit.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_NHbjX4WPJ1oj6DSCAmdiHYQz\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f626104688193a4b287a1a5cf7568\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"schemas/public_summary.schema.json\\\",\\\"offset\\\":0,\\\"limit\\\":4000}\",\n  \"call_id\": \"call_YlVNG4Ap1OCvERC6LRc0xeE8\",\n  \"name\": \"read_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "call_hsErmQpwqizB6EnArXi4uDy1"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "call_RXuyz4bLRs0ozrrDTXwNiUDP"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "call_FJjNGkDoE2iZ2LsYioCCnGNF"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "call_NHbjX4WPJ1oj6DSCAmdiHYQz"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": 0,
              "limit": 4000
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "call_YlVNG4Ap1OCvERC6LRc0xeE8"
          }
        ],
        "usage": {
          "promptTokens": 1212,
          "cachedTokens": 1024,
          "responseTokens": 165,
          "thinkingTokens": 0,
          "totalTokens": 1377
        },
        "costUsd": 0.0028182
      },
      {
        "step": 5,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f62ac9758819387d5c9c45e4dad8f\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/study_overview.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"paper\\\\\\\": {\\\\n    \\\\\\\"title\\\\\\\": \\\\\\\"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\\\\\\\",\\\\n    \\\\\\\"doi\\\\\\\": \\\\\\\"10.1038/s41586-025-09006-8\\\\\\\",\\\\n    \\\\\\\"publication_year\\\\\\\": 2025,\\\\n    \\\\\\\"domain\\\\\\\": \\\\\\\"oncology-immunology\\\\\\\",\\\\n    \\\\\\\"study_type\\\\\\\": \\\\\\\"preclinical+retrospective\\\\\\\"\\\\n  },\\\\n  \\\\\\\"core_question\\\\\\\": \\\\\\\"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory tumor state that improves sensitivity to anti-PD-L1 immune checkpoint blockade?\\\\\\\",\\\\n  \\\\\\\"datasets_or_cohorts\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-efficacy-combo\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse efficacy cohort (combination therapy)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"78 tumor-bearing mice (pooled across repeat experiments)\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Preclinical efficacy set of tumor-bearing mice treated with an intratumoral mRNA vaccine in combination with anti-PD-L1, pooled across repeated experiments to evaluate tumor control.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"mouse-controls\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Mouse control cohort (vaccine only, ICI only, vehicle)\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"84 tumor-bearing mice (matched controls, pooled)\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Matched preclinical control mice receiving vaccine-only, ICI-only, or vehicle conditions, used to benchmark whether the combination effect exceeds single-agent activity.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-retrospective\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human retrospective metastatic cohort\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"130 patients total\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Retrospective, non-randomized translational cohort of metastatic patients receiving immune checkpoint inhibitor treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-vaccinated\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human vaccinated subgroup\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"43 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination, used for survival comparison under ICI treatment.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"human-unvaccinated\\\\\\\",\\\\n      \\\\\\\"label\\\\\\\": \\\\\\\"Human unvaccinated subgroup\\\\\\\",\\\\n      \\\\\\\"sample_size_or_observations\\\\\\\": \\\\\\\"87 patients\\\\\\\",\\\\n      \\\\\\\"description\\\\\\\": \\\\\\\"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, serving as the comparator group for outcomes under ICI therapy.\\\\\\\" \\\\n    }\\\\n  ],\\\\n  \\\\\\\"major_limitations\\\\\\\": [\\\\n    \\\\\\\"The human analysis was retrospective and non-randomized, so residual confounding is likely.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to ICI initiation varied across patients, complicating interpretation.\\\\\\\",\\\\n    \\\\\\\"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\\\\\\\",\\\\n    \\\\\\\"Mouse model effects may not map one-to-one to all human tumors.\\\\\\\",\\\\n    \\\\\\\"Some mechanistic readouts were strongest in specific model systems rather than uniformly across settings.\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_plhYRXmGu5V88qSOITX50Yr2\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f62ac976481938a0ab20e7016f820\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/quantitative_findings.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"findings\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q01\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of tumor proteins represented in immunopeptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"62.3%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"37.3%\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination was associated with broader tumor antigen display in the immunopeptidome than the comparator condition.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L28\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q02\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Fraction of proteins represented in MHC-I peptidome\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"40.6%\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"20.6%\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"The MHC-I-presented peptide landscape was substantially expanded after intratumoral mRNA vaccination relative to comparator.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L29\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q03\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Retrospective human survival comparison p-value under ICI\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"p=0.01\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"N/A\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"In a retrospective cohort, prior SARS-CoV-2 mRNA vaccination was associated with improved survival for patients receiving ICI treatment.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L30\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q04\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Type I interferon response score (normalized units)\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"3.1\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"Tumors showed a marked induction of a type I interferon response after mRNA vaccination compared with baseline.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L31\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q05\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"PD-L1 expression fold-change in tumor tissue\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"2.4x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"PD-L1 expression increased after intratumoral mRNA vaccination, supporting a rationale for anti-PD-L1 combination therapy.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L32\\\\\\\"]\\\\n    },\\\\n    {\\\\n      \\\\\\\"id\\\\\\\": \\\\\\\"Q06\\\\\\\",\\\\n      \\\\\\\"metric\\\\\\\": \\\\\\\"Intratumoral CD8+ T-cell density fold-change\\\\\\\",\\\\n      \\\\\\\"value\\\\\\\": \\\\\\\"1.8x\\\\\\\",\\\\n      \\\\\\\"comparator_or_baseline\\\\\\\": \\\\\\\"1.0x\\\\\\\",\\\\n      \\\\\\\"interpretation\\\\\\\": \\\\\\\"CD8+ T-cell infiltration in tumors increased with combination treatment compared with baseline.\\\\\\\",\\\\n      \\\\\\\"evidence_line_refs\\\\\\\": [\\\\\\\"L33\\\\\\\"]\\\\n    }\\\\n  ],\\\\n  \\\\\\\"controls_or_null_results\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L36\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"ICI-only treatment had limited activity in low-immunogenic baseline settings.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L37\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L38\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"statement\\\\\\\": \\\\\\\"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n      \\\\\\\"evidence_line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n    }\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_3moYxhL1ruth5AJ4GcFbJD5W\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f62ac976c81938cb0f41012e7eb37\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/claim_audit.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"claims\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C01\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"In preclinical mouse tumor models, an intratumoral mRNA vaccine combined with anti-PD-L1 is reported to improve tumor control compared with control conditions.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L14\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L46\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"Mouse model effects may not map one-to-one to all human tumors, so efficacy in mice does not guarantee clinical benefit.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C02\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"In a retrospective metastatic patient cohort treated with immune checkpoint inhibitors, prior SARS-CoV-2 mRNA vaccination status is associated with better survival.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"tentative\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L15\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L30\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"Because the human analysis is retrospective and non-randomized and vaccination timing varied, the association cannot be interpreted as a definitive causal effect.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C03\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination is reported to broaden tumor antigen presentation, increasing the fraction of tumor proteins observed in immunopeptidomics and in the MHC-I peptidome.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L28\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L29\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C04\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"The authors propose that intratumoral mRNA vaccination triggers type I interferon signaling in tumors, contributing to improved immune priming for checkpoint blockade.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L42\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L31\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"The report summarizes a proposed mechanistic chain; without full experimental detail here, the magnitude and generality of interferon induction across models could vary.\\\\\\\" \\\\n    },\\\\n    {\\\\n      \\\\\\\"claim_id\\\\\\\": \\\\\\\"C05\\\\\\\",\\\\n      \\\\\\\"claim\\\\\\\": \\\\\\\"Type I interferon signaling appears necessary for the sensitization effect, because IFNAR1 blockade is reported to eliminate the benefit.\\\\\\\",\\\\n      \\\\\\\"strength\\\\\\\": \\\\\\\"moderate\\\\\\\",\\\\n      \\\\\\\"evidence\\\\\\\": [\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L39\\\\\\\"\\\\n        },\\\\n        {\\\\n          \\\\\\\"quote\\\\\\\": \\\\\\\"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\\\\\\\",\\\\n          \\\\\\\"line_ref\\\\\\\": \\\\\\\"L42\\\\\\\"\\\\n        }\\\\n      ],\\\\n      \\\\\\\"caveat\\\\\\\": \\\\\\\"This necessity claim is based on a specific perturbation (anti-IFNAR1) described in summary form, and may depend on tumor model context and experimental conditions.\\\\\\\" \\\\n    }\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_GYAtpArleIf2qzcTuab7u6XN\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n[tool-call]\\n{\n  \"id\": \"fc_072a216b97af7cf000698f62ac97708193ab456a4037dc8334\",\n  \"type\": \"function_call\",\n  \"status\": \"completed\",\n  \"arguments\": \"{\\\"file_path\\\":\\\"output/public_summary.json\\\",\\\"content\\\":\\\"{\\\\n  \\\\\\\"headline\\\\\\\": \\\\\\\"Intratumoral mRNA vaccination may prime tumors for stronger checkpoint blockade\\\\\\\",\\\\n  \\\\\\\"plain_language_summary\\\\\\\": \\\\\\\"Immune checkpoint inhibitors (such as anti-PD-L1 therapies) can work very well for some cancers, but many tumors do not respond because the immune system is not strongly activated against them. This study reports that delivering an mRNA vaccine directly into tumors can create an interferon-driven inflammatory state that helps the immune system recognize the tumor and may make checkpoint blockade more effective. In mouse tumor models, the combination of intratumoral mRNA vaccination and anti-PD-L1 is described as improving tumor control, alongside signs of increased immune activity within the tumor. The report also summarizes a retrospective (non-randomized) analysis of 130 metastatic patients treated with checkpoint inhibitors, where those with prior SARS-CoV-2 mRNA vaccination (43 patients) had better survival than unvaccinated patients (87 patients), with a reported p-value of 0.01. Because the human results are observational and the timing and clinical backgrounds varied across patients, the findings support a promising biological hypothesis but do not yet justify changes to clinical practice without prospective trials.\\\\\\\",\\\\n  \\\\\\\"what_is_new\\\\\\\": [\\\\n    \\\\\\\"Links intratumoral mRNA vaccination to a tumor interferon response that could enhance ICI sensitivity.\\\\\\\",\\\\n    \\\\\\\"Reports broader MHC-I peptide presentation after vaccination, suggesting improved tumor visibility to T cells.\\\\\\\",\\\\n    \\\\\\\"Includes a translational retrospective patient comparison by SARS-CoV-2 mRNA vaccination status during ICI.\\\\\\\" \\\\n  ],\\\\n  \\\\\\\"why_caution_is_needed\\\\\\\": [\\\\n    \\\\\\\"The human analysis is retrospective and non-randomized, so differences between groups could explain outcomes.\\\\\\\",\\\\n    \\\\\\\"Vaccination timing relative to checkpoint inhibitor treatment varied, making cause-and-effect unclear.\\\\\\\",\\\\n    \\\\\\\"Mouse model results may not translate directly to diverse human tumor types and treatment histories.\\\\\\\" \\\\n  ],\\\\n  \\\\\\\"glossary\\\\\\\": [\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Immune checkpoint inhibitor (ICI)\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A cancer drug that removes inhibitory signals on immune cells (for example PD-1/PD-L1) to help them attack tumors.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Anti-PD-L1\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A type of checkpoint therapy that blocks PD-L1, a molecule tumors can use to suppress T-cell activity.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Intratumoral mRNA vaccine\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"An mRNA-based formulation injected into a tumor to stimulate local immune sensing and immune activation in the tumor environment.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"Type I interferon\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"A family of immune signaling proteins that can induce antiviral-like inflammation and enhance antigen presentation to T cells.\\\\\\\"\\\\n    },\\\\n    {\\\\n      \\\\\\\"term\\\\\\\": \\\\\\\"MHC-I peptidome\\\\\\\",\\\\n      \\\\\\\"definition\\\\\\\": \\\\\\\"The collection of peptides displayed on MHC class I molecules, which helps CD8+ T cells detect abnormal or tumor-derived proteins.\\\\\\\"\\\\n    }\\\\n  ],\\\\n  \\\\\\\"open_questions\\\\\\\": [\\\\n    \\\\\\\"Would a prospective randomized trial confirm improved outcomes when combining intratumoral mRNA vaccination with ICIs?\\\\\\\",\\\\n    \\\\\\\"Which tumor types and baseline immune states benefit most from the interferon-driven priming described here?\\\\\\\",\\\\n    \\\\\\\"What is the safest and most effective timing and dosing of intratumoral mRNA vaccination relative to ICI therapy?\\\\\\\"\\\\n  ]\\\\n}\\\\n\\\"}\",\n  \"call_id\": \"call_abVBqcn6R93POW0XdEsZhLzN\",\n  \"name\": \"write_file\",\n  \"parsed_arguments\": null\n}\\n",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory tumor state that improves sensitivity to anti-PD-L1 immune checkpoint blockade?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice (pooled across repeat experiments)\",\n      \"description\": \"Preclinical efficacy set of tumor-bearing mice treated with an intratumoral mRNA vaccine in combination with anti-PD-L1, pooled across repeated experiments to evaluate tumor control.\" \n    },\n    {\n      \"id\": \"mouse-controls\",\n      \"label\": \"Mouse control cohort (vaccine only, ICI only, vehicle)\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice (matched controls, pooled)\",\n      \"description\": \"Matched preclinical control mice receiving vaccine-only, ICI-only, or vehicle conditions, used to benchmark whether the combination effect exceeds single-agent activity.\" \n    },\n    {\n      \"id\": \"human-retrospective\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients total\",\n      \"description\": \"Retrospective, non-randomized translational cohort of metastatic patients receiving immune checkpoint inhibitor treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\" \n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort with prior SARS-CoV-2 mRNA vaccination, used for survival comparison under ICI treatment.\" \n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subset of the retrospective metastatic cohort without prior SARS-CoV-2 mRNA vaccination, serving as the comparator group for outcomes under ICI therapy.\" \n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis was retrospective and non-randomized, so residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients, complicating interpretation.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across settings.\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "call_plhYRXmGu5V88qSOITX50Yr2"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Intratumoral mRNA vaccination was associated with broader tumor antigen display in the immunopeptidome than the comparator condition.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"The MHC-I-presented peptide landscape was substantially expanded after intratumoral mRNA vaccination relative to comparator.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value under ICI\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"In a retrospective cohort, prior SARS-CoV-2 mRNA vaccination was associated with improved survival for patients receiving ICI treatment.\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Tumors showed a marked induction of a type I interferon response after mRNA vaccination compared with baseline.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"PD-L1 expression increased after intratumoral mRNA vaccination, supporting a rationale for anti-PD-L1 combination therapy.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"CD8+ T-cell infiltration in tumors increased with combination treatment compared with baseline.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "call_3moYxhL1ruth5AJ4GcFbJD5W"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"In preclinical mouse tumor models, an intratumoral mRNA vaccine combined with anti-PD-L1 is reported to improve tumor control compared with control conditions.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\",\n          \"line_ref\": \"L14\"\n        },\n        {\n          \"quote\": \"5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, so efficacy in mice does not guarantee clinical benefit.\" \n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"In a retrospective metastatic patient cohort treated with immune checkpoint inhibitors, prior SARS-CoV-2 mRNA vaccination status is associated with better survival.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        },\n        {\n          \"quote\": \"| Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\",\n          \"line_ref\": \"L30\"\n        }\n      ],\n      \"caveat\": \"Because the human analysis is retrospective and non-randomized and vaccination timing varied, the association cannot be interpreted as a definitive causal effect.\" \n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Intratumoral mRNA vaccination is reported to broaden tumor antigen presentation, increasing the fraction of tumor proteins observed in immunopeptidomics and in the MHC-I peptidome.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"| Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"| Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\" \n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"The authors propose that intratumoral mRNA vaccination triggers type I interferon signaling in tumors, contributing to improved immune priming for checkpoint blockade.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"| Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\",\n          \"line_ref\": \"L31\"\n        }\n      ],\n      \"caveat\": \"The report summarizes a proposed mechanistic chain; without full experimental detail here, the magnitude and generality of interferon induction across models could vary.\" \n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"Type I interferon signaling appears necessary for the sensitization effect, because IFNAR1 blockade is reported to eliminate the benefit.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"- Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        },\n        {\n          \"quote\": \"1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        }\n      ],\n      \"caveat\": \"This necessity claim is based on a specific perturbation (anti-IFNAR1) described in summary form, and may depend on tumor model context and experimental conditions.\" \n    }\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "call_GYAtpArleIf2qzcTuab7u6XN"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"Intratumoral mRNA vaccination may prime tumors for stronger checkpoint blockade\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors (such as anti-PD-L1 therapies) can work very well for some cancers, but many tumors do not respond because the immune system is not strongly activated against them. This study reports that delivering an mRNA vaccine directly into tumors can create an interferon-driven inflammatory state that helps the immune system recognize the tumor and may make checkpoint blockade more effective. In mouse tumor models, the combination of intratumoral mRNA vaccination and anti-PD-L1 is described as improving tumor control, alongside signs of increased immune activity within the tumor. The report also summarizes a retrospective (non-randomized) analysis of 130 metastatic patients treated with checkpoint inhibitors, where those with prior SARS-CoV-2 mRNA vaccination (43 patients) had better survival than unvaccinated patients (87 patients), with a reported p-value of 0.01. Because the human results are observational and the timing and clinical backgrounds varied across patients, the findings support a promising biological hypothesis but do not yet justify changes to clinical practice without prospective trials.\",\n  \"what_is_new\": [\n    \"Links intratumoral mRNA vaccination to a tumor interferon response that could enhance ICI sensitivity.\",\n    \"Reports broader MHC-I peptide presentation after vaccination, suggesting improved tumor visibility to T cells.\",\n    \"Includes a translational retrospective patient comparison by SARS-CoV-2 mRNA vaccination status during ICI.\" \n  ],\n  \"why_caution_is_needed\": [\n    \"The human analysis is retrospective and non-randomized, so differences between groups could explain outcomes.\",\n    \"Vaccination timing relative to checkpoint inhibitor treatment varied, making cause-and-effect unclear.\",\n    \"Mouse model results may not translate directly to diverse human tumor types and treatment histories.\" \n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A cancer drug that removes inhibitory signals on immune cells (for example PD-1/PD-L1) to help them attack tumors.\"\n    },\n    {\n      \"term\": \"Anti-PD-L1\",\n      \"definition\": \"A type of checkpoint therapy that blocks PD-L1, a molecule tumors can use to suppress T-cell activity.\"\n    },\n    {\n      \"term\": \"Intratumoral mRNA vaccine\",\n      \"definition\": \"An mRNA-based formulation injected into a tumor to stimulate local immune sensing and immune activation in the tumor environment.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A family of immune signaling proteins that can induce antiviral-like inflammation and enhance antigen presentation to T cells.\"\n    },\n    {\n      \"term\": \"MHC-I peptidome\",\n      \"definition\": \"The collection of peptides displayed on MHC class I molecules, which helps CD8+ T cells detect abnormal or tumor-derived proteins.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Would a prospective randomized trial confirm improved outcomes when combining intratumoral mRNA vaccination with ICIs?\",\n    \"Which tumor types and baseline immune states benefit most from the interferon-driven priming described here?\",\n    \"What is the safest and most effective timing and dosing of intratumoral mRNA vaccination relative to ICI therapy?\"\n  ]\n}\n"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "call_abVBqcn6R93POW0XdEsZhLzN"
          }
        ],
        "usage": {
          "promptTokens": 5407,
          "cachedTokens": 1152,
          "responseTokens": 3490,
          "thinkingTokens": 1870,
          "totalTokens": 10767
        },
        "costUsd": 0.08268785
      },
      {
        "step": 6,
        "modelVersion": "gpt-5.2-2025-12-11",
        "text": "- [x] `output/study_overview.json` written\n- [x] `output/quantitative_findings.json` written\n- [x] `output/claim_audit.json` written\n- [x] `output/public_summary.json` written",
        "toolCalls": [],
        "usage": {
          "promptTokens": 10844,
          "cachedTokens": 10624,
          "responseTokens": 60,
          "thinkingTokens": 461,
          "totalTokens": 11365
        },
        "costUsd": 0.0095382
      }
    ],
    "totalCostUsd": 0.10158224999999999
  }
}
